Editorial: stratifying risk of adverse outcomes in cirrhosis-the Hepquant SHUNT test. Authors' reply
Aliment Pharmacol Ther
.
2021 Apr;53(8):941-942.
doi: 10.1111/apt.16311.
Authors
Sumeet K Asrani
1
,
Gregory T Everson
2
3
Affiliations
1
Department of Hepatology and Liver Transplantation, Baylor University Medical Center, Dallas, TX, USA.
2
Division of Gastroenterology and Hepatology, University of Colorado Denver School of Medicine, Aurora, CO, USA.
3
HepQuant LLC, Greenwood Village, CO, USA.
PMID:
33745171
DOI:
10.1111/apt.16311
No abstract available
Publication types
Editorial
Comment
MeSH terms
Fistula*
Humans
Liver Cirrhosis* / complications
Liver Cirrhosis* / diagnosis